Over the coming months, Citron Research will release a series of articles on Questcor Pharmaceuticals Inc (NASDAQ:QCOR) intended to shed light on probable issues of interest to the multi-pronged investigation underway by multiple regulatory agencies into numerous aspects of Questcor’s business strategy that political correct-speak would deem “legally challenged”. These articles will dig deeper into topics such as:
- The Chronic Disease Fund, and the role it plays in contributing to Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s revenues
- Medicare billing (it is very dangerous to participate in a scheme to defraud the Federal Government)
- Insurance reimbursement coding for Acthar
Meanwhile, today’s question is whether Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s Synacthen acquisition is anti-competitive. The points raised in Citron’s article last week are relevant to the FTC’s inquiry, demonstrating Questcor’s intent to suppress competition by acquiring Synacthen is exposed by their own sell-side analysts.
We are sure that Questcor Pharmaceuticals Inc (NASDAQ:QCOR) will now try to posture to the FTC that Synacthen is a completely different drug, arguing that while it has similarities, it cannot be regarded as a replacement for HP Acthar Gel. This piece of evidence presented below is for the FTC, so shareholders please cover your eyes.
DG Value Surges On Recovery Plays
According to a copy of the firm's February investor update, Dov Gertzulin's DG Value Partners returned +4.48% net for the month of February, which ValueWalk has been able to review. Q4 2020 hedge fund letters, conferences and more Following this performance, the firm has returned +8.32% net for the year to the end of February. Read More
See full PDF here.